Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacyclic’s Co-Development Pact With Janssen Carries Largest Single-Asset Upfront Payment Of 2011

This article was originally published in The Pink Sheet Daily

Executive Summary

The two companies will co-develop and co-commercialize PCI-32765, which is being investigated in multiple types of hematological cancer.

You may also be interested in...



J&J’s Oncology Strategy: Aim For Next-Gen Immuno-Oncology, More M&A

Johnson & Johnson has built a strong oncology business by making smart partnering plays. Now the company is looking to write a new chapter, building on its single-asset successes with a portfolio of new cancer drugs developed both internally and through more M&A.

Ibrutinib Results Suggest Potential To Shake Up CLL Market

Momentum builds for Pharmacyclics/J&J’s ibrutinib with release of new data at the American Society of Hematology meeting, suggesting the drug has a shot at accelerated approval in sub-populations with high unmet need and potential in a range of B-cell cancers. Profiles of competitors from Gilead and Infinity/Takeda also came into greater focus at ASH.

ASH Data Raise Hopes For Ibrutinib As Single Agent, Chemo-Free Option In CLL

With the latest response, safety and durability data creating a buzz at the American Society of Hematology, Pharmacyclics CMO Lori Anne Kunkel discusses possibility for accelerated approval in a high-risk type of chronic lymphocytic leukemia. Drug also shows promise in trials of a genetic subtype of diffuse large B-cell lymphoma and mantle cell lymphoma.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM006051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel